Voyager Therapeutics, Inc.

This Current Report on Form 8-K (including Exhibit 99.1 and Exhibit 99.2) contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “expect,” “anticipate,” “potential,” “may,” “plan,” “future,” “suggest,” “would,” “believe,” “will,” or “continue,” and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about expectations for the Company’s achievement of preclinical and clinical development milestones for its potential development candidates, such as the identification of lead development candidates, IND and CTA filings, the initiation of clinical trials, and the generation of clinical data and proof-of-concept data; the potential for third-party clinical data to inform the Company’s product development programs; the Company’s ability to expand beyond gene therapy and antibodies into other modalities of neurogenetic medicine, including Voyager NeuroShuttles and small molecule therapies; the Company’s ability to generate near-term and long-term funding through reimbursement, upfront, milestone and royalty-based fees (as applicable) under its existing licensing and collaboration agreements, and to obtain data regarding the performance of its TRACER-derived capsid families licensed to its collaborators and partners under such agreements; the Company’s ability to maintain and advance product development programs under its current partnerships and collaborations, including the anticipated timing of regulatory submissions by collaborators; and the sufficiency of the Company’s cash resources.

These forward-looking statements are only predictions, and the Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements. All forward-looking statements are based on estimates and assumptions by the Company’s management that, although the Company believes such forward-looking statements to be reasonable, are inherently uncertain and subject to risks and uncertainties that may cause actual results to differ materially from those that the Company expected. Such risks and uncertainties include, among others, the expectations and decisions of regulatory authorities; the timing, initiation, conduct, and outcomes of the Company’s preclinical studies and clinical trials; the availability of data from internal or third-party clinical trials; the success of the Company’s product candidates; the availability or commercial potential of product candidates under collaborations; the willingness and ability of the Company’s collaboration partners to meet obligations under collaboration agreements with the Company; the continued development of the Company’s technology platforms, including the Company’s TRACER capsid discovery platform and its non-viral discovery platform; the Company’s scientific approach and program development progress, and the restricted supply and increased costs of critical research components; the development by third parties of capsid identification platforms and capsids that may be competitive to the Company’s TRACER capsid discovery platform; the Company’s ability to create and protect intellectual property rights associated with the TRACER capsid discovery and non-viral platforms, the capsids and ligands identified by the platforms, and development candidates for the Company’s pipeline programs; the possibility and the timing of the Company’s receipt of program reimbursement, development or commercialization milestones, option exercise, and other payments under the Company’s existing licensing or collaboration agreements; the ability of the Company to negotiate and complete licensing or collaboration agreements with other parties on terms acceptable to the Company and the third parties; the success of programs controlled by third-party collaborators in which the Company retains a financial interest; the ability to attract and retain talented directors, employees, and contractors; and the sufficiency of the Company’s cash resources.

These statements are also subject to a number of material risks and uncertainties that are described in the Company’s most recent Annual Report on Form 10-K filed with the SEC, as updated by its subsequent filings with the SEC. All information in this Form 8-K (including Exhibit 99.1 and Exhibit 99.2) is as of the date of this Form 8-K, and any forward-looking statement speaks only as of the date on which it was made. The Company undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.